Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

Joong Won Park, Richard S. Finn, Jun Suk Kim, Mark Karwal, Ruby K. Li, Fuad Ismail, Melanie Thomas, Rosemarie Harris, Christine Baudelet, Ian Walters, Jean Luc Raoul

Research output: Contribution to journalArticlepeer-review

130 Citations (Scopus)

Fingerprint Dive into the research topics of 'Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences